

Clinical Trial Protocol

Iranian Registry of Clinical Trials

13 Jul 2026

A randomised, double-blind, single-dose, active-controlled, crossover study in healthy subjects to demonstrate pharmacokinetic equivalence of Altebrel™ (produced by AryoGen Pharmed) and Enbrel:registered:(produced by Amgen Company)

Protocol summary

Summary

This is a single-dose trial with one administration of each product (Altebrel™ and Enbrel®). Each subject will participate in two treatment periods, and will be randomised to receive Altebrel™ or Enbrel® in a crossover fashion. The subjects will be hospitalized in the trial site for 24 hours after dosing for serial pharmacokinetic sampling. The subjects will be requested to visit the trial site 36, 48, 60, 72, 96, 120, 144, 168, 216, 312 and 480 h after dose administration for blood sampling and evaluation of safety variable and tolerability.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2016033021315N4**

Registration date: **2017-06-06, 1396/03/16**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2017-06-06, 1396/03/16

Registrant information

Name

Nassim Anjidan

Name of organization / entity

Orchid Pharmed

Country

Iran (Islamic Republic of)

Phone

+98 21 4347 3000

Email address

amini@orchidpharmed.com

Recruitment status

Recruitment complete

Funding source

AryoGen Pharmed company

Expected recruitment start date

2016-12-04, 1395/09/14

Expected recruitment end date

2017-03-15, 1395/12/25

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

A randomised, double-blind, single-dose, active-controlled, crossover study in healthy subjects to demonstrate pharmacokinetic equivalence of Altebrel™ (produced by AryoGen Pharmed) and Enbrel:registered:(produced by Amgen Company)

Public title

Comparison between Altebrel™ and Enbrel®

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion: 1)Provide written IC to participate in the trial and to comply with the trial procedures. 2)Take written informed consent to participate in the trial and to abide by the trial restrictions. 3)Be healthy male between the ages of 18 and 55 years. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, complete physical examination including blood pressure and heart rate measurement, 12 lead

ECG and clinical laboratory tests. 4)Have a body mass index between 20.0 and 30 kg/m², inclusive 5)Have Chest X-ray with no evidence of current, active TB or previous (inactive) TB, general infections, heart failure, malignancy, or other clinically significant abnormalities taken at Screening or within 24 weeks prior to Day 1 and read by a qualified radiologist. Exclusion: 1.Being doubtful about their availability to complete the trial. 2.history and/or current presence of clinical significant atopic allergy, hypersensitivity or allergic reactions, also including known or suspected clinically relevant drug hypersensitivity to any components of the test and reference IMP formulation or comparable drugs. 3.Active or latent Tuberculosis or who have a history of Tuberculosis. 4.history of invasive systemic fungal infections or other opportunistic infections 5.systemic or local infection, a known risk for developing sepsis and/or known active inflammatory process 6.serious infection associated with hospitalisation and/or which required intravenous antibiotics 7.history of and/or current cardiac disease 8.Have received live vaccine(s) within 30 days prior to Screening or who will require live vaccine(s) between Screening and the final study visit. 9.Intake medication with a half-life > 24 h within 1 month or 5 half-lives of the medication prior to the first administration of IMP. 10.Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody. A positive test for HIV antibody. 11.History of CNS demyelinating disorders in family (MS) 12.Have a history of smoking >10 cigarettes per day	Tehran University of medical science Street address District 6, Poursina St. City Tehran Postal code Approval date 2017-04-18, 1396/01/29 Ethics committee reference number IR.TUMS.VCR.REC.1396.2089
Age From 18 years old to 55 years old Gender Male Phase 1 Groups that have been masked <i>No information</i> Sample size Target sample size: 34 Randomization (investigator's opinion) Randomized Randomization description Blinding (investigator's opinion) Double blinded Blinding description Placebo Not used Assignment Crossover Other design features	Health conditions studied 1 Description of health condition studied rheumatoid arthritis ICD-10 code M05, M06.9 ICD-10 code description Seropositive rheumatoid arthritis, Rheumatoid arthritis, unspecified Primary outcomes 1 Description Cmax of etanercept Timepoint 0, 6, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 216, 312 and 480 hours Method of measurement ELISA
Secondary Ids empty Ethics committees 1 Ethics committee Name of ethics committee	2 Description AUC infinite of etanercept Timepoint 0, 6, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 216, 312 and 480 hours Method of measurement Calculation Secondary outcomes 1 Description AUClast of etanercept Timepoint 0, 6, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 216, 312 and 480 hours Method of measurement calculation 2 Description tmax of etanercept Timepoint

0, 6, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 216, 312
and 480 hours

Method of measurement

calculation

3

Description

t½ of etanercept

Timepoint

0, 6, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 216, 312
and 480 hours

Method of measurement

calculation

4

Description

Volume of distribution (VD) of etanercept

Timepoint

0, 6, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 216, 312
and 480 hours

Method of measurement

calculation

5

Description

Clearance (CL) of etanercept

Timepoint

0, 6, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 216, 312
and 480 hours

Method of measurement

calculation

6

Description

Adverse events (AE)

Timepoint

0, 6, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 216, 312
and 480 hours

Method of measurement

physical Examination

Intervention groups

1

Description

a prefilled syringe dose of AltebreITM (25 mg/0.5mL) to
be administered as a single subcutaneous injection

Category

Treatment - Drugs

2

Description

a prefilled syringe dose of Enbrel® (25 mg/0.51mL) to be
administered as a single subcutaneous injection

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Orchid Pahrmed Company

Full name of responsible person

Somayeh Amini

Street address

4th floor, No. 74, Across Faculty of Food Technology
Shahid Beheshti University, Shahid Hafezi Street,
Farahzadi Blvd., Shahrake Gharb

City

Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

AryoGen Pharmed Company

Full name of responsible person

Somayeh Amini

Street address

no 2, Emad Khorassani D.D, Derakhti St, Dadman
Blvd, Shahrake Gharb

City

Tehran

Grant name

Grant code / Reference number

**Is the source of funding the same sponsor
organization/entity?**

Yes

Title of funding source

AryoGen Pharmed Company

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Orchid Pharmed Company

Full name of responsible person

Somayeh Amini

Position

MedicalDepartment Manager/Pharm.D

Other areas of specialty/work

Street address

no 2, Emad khorassani D.D, Derakhti St, Dadman
Blvd, Shahrake Gharb

City
Tehran
Postal code
1468813112
Phone
+98 21 4347 3210
Fax
Email
Amini.s@orchidpharmed.com
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Rheumatology Research Center, Doctor Shariati Hospital
Full name of responsible person
Ahmadreza Jamshidi
Position
Head of Rheumatology center Department/MD, PhD of Rheumatology
Other areas of specialty/work
Street address
Rheumatology Research Center, Doctor Shariati Hospital, North Kargar Avenue
City
Tehran
Postal code
1411713137
Phone
+98 21 8822 0065
Fax
Email
jamshida@sina.tums.ac.ir
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Orchid Pharmed Company
Full name of responsible person
Somayeh Amini
Position
Medical Department Manager/Pharm.D
Other areas of specialty/work
Street address
no 2, Emad khorassani D.D, Derakhti St, Dadman Blvd, shahrake Gharb
City
Tehran
Postal code
1468813112
Phone
+98 21 4347 3210
Fax
Email
Amini.s@orchidpharmed.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty